QBiotics leadership transition
BRISBANE, 23 October 2024
- Sue Foden returns to the role of Non-Executive Chair of the Board
- CEO Stephen Doyle appointed to the Board of Directors as Managing Director
- Co-founder, Victoria Gordon retires from QBiotics’ executive team while remaining on the Board as a Non-Executive Director.
As part of its leadership transition, the Board of QBiotics is pleased to announce the following changes with effect from 22 October 2024.
Dr Sue Foden, who has been fulfilling an executive role overseeing the Company’s operations throughout the CEO recruitment process as Executive Chair, will return to the role of Non-Executive Chair. Sue’s leadership during this time has been instrumental for preserving the Company’s momentum and ensuring its continued stability.
CEO, Stephen Doyle has been appointed to the board of directors as Managing Director.
Dr Victoria Gordon has retired from her position of Executive Director, Strategic Alliances and Investor Relations and will remain on the board as Non-Executive Director. In addition, to ensure smooth transition, Victoria will be available to support Stephen and the senior management team.
Victoria’s valuable contributions and strategic vision have been pivotal in shaping the Company since its inception. As a Non-Executive Director, Victoria will continue to contribute to QBiotics' strategic direction - her ongoing presence on the Board ensures continuity and enables the Board to draw upon her deep experience, insights and corporate knowledge.
Sue Foden shared her thanks and appreciation of Victoria’s continued involvement, stating, "My thanks go to our Co-founder, Victoria Gordon who will now step away from a QBiotics executive role, while remaining on the Board as Non-Executive Director. We are immensely proud of the many achievements Victoria has overseen through her executive career with the company and are fortunate to retain her skillset and knowledge at the Board level. I extend a warm welcome to her as a Non-Executive Director and look forward to working with her in this new role.”
Victoria Gordon responded "I am incredibly proud of everything we’ve achieved to date at QBiotics. With Stephen now in the role of CEO and Managing Director, I am confident that the business is in safe hands to deliver upon our clinical and commercial milestones. I look forward to supporting both Stephen and the Board as the Company moves forward.”
—ends—
FURTHER INFORMATION
SUE FODEN, CHAIR OF THE BOARD
communications@qbiotics.com or
MEDIA ENQUIRIES / NOTES FOR EDITORS
JANE LOWE, IR DEPARTMENT
jane.lowe@irdepartment.com.au +61 411 117 774
ABOUT QBIOTICS
QBiotics is an unlisted public Australian life sciences company that specialises in the discovery and development of novel cell signalling small molecules. QBiotics applies phenotypic screening to generate breakthrough innovation in the discovery of first in class solutions to challenging medical conditions. Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds.
QBiotics’ lead oncology drug, tigilanol tiglate, is a small molecule targeting a range of solid tumours and is currently in human clinical Phase II development. A veterinary formulation of tigilanol tiglate is registered and marketed as an oncology pharmaceutical, under the trade name STELFONTA®, in the USA, Europe, the UK and Australia.
QBiotics’ lead wound healing drug candidate, EBC 1013 is a small molecule targeting a range of wounds including chronic and acute wounds and burns. A first-in-human Phase I clinical development in patients with venous leg ulcers is open for recruitment.